However, no relationship between MLH1 methylation-mediated loss of protein and resistance to systemic cisplatin treatment could be demonstrated in testicular cancer tissue [63], suggesting that the relevance of MLH1 methylation for cisplatin resistance might be tumor-type specific. Here, MLH1 is linked to testicular cancer.